Insight, China's Pharmaceutical Industry

Qyuns Therapeutics Receives NMPA Trial Approvals for QX027N – Long‑Acting Bispecific Antibody Targeting Asthma and Atopic Dermatitis

Qyuns Therapeutics Co., Ltd. (HKG: 2509) announced that China’s National Medical Products Administration (NMPA) has...

Suzhou Zelgen Secures NMPA Trial Approval for ZG006 (Alveltamig) – First‑In‑Class Trispecific Antibody for Advanced Neuroendocrine Carcinoma

Fineline Cube Nov 15, 2025

Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that China’s National Medical Products Administration (NMPA)...

Company Deals

Adagene Licenses SAFEbody Platform to Third Arc Bio for Masked CD3 T‑Cell Engagers

Fineline Cube Nov 14, 2025

Adagene Inc. (NASDAQ: ADAG) and Third Arc Bio, Inc. announced today that they have signed...

Company Drug

Gan & Lee’s Ondibta Receives Positive CHMP Opinion – EU Biosimilar Pathway Opened

Fineline Cube Nov 14, 2025

Gan & Lee Pharmaceuticals Co., Ltd. (SHA: 603087) announced that the European Medicines Agency (EMA) has...

Company Drug

Corxel Secures FDA IND Clearance for CX11 Phase 2 Trial in Type 2 Diabetes

Fineline Cube Nov 14, 2025

Corxel Pharmaceuticals Limited announced today that the U.S. Food and Drug Administration (FDA) has cleared...

Company Deals

Pfizer Reduces BioNTech Holding by 54.7% While Collaboration Remains Intact

Fineline Cube Nov 14, 2025

Pfizer Inc. (NYSE: PFE) disclosed on November 13, 2025 that it has sold a portion of its...

Company Drug

Jiangsu Hengrui’s Rezvilutamide Clears NMPA Hurdle, Moves Into Phase III Prostate‑Cancer Trial

Fineline Cube Nov 14, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced today that its second‑generation androgen‑receptor inhibitor...

Company Drug

Legend Biotech Reports $524 M CARVYKTI Sales, FDA Updates & Q3 Loss

Fineline Cube Nov 13, 2025

Legend Biotech (NASDAQ: LEGN) published the unaudited financial results for fiscal Quarter 3 2025 (2025Q3) on 12 Nov 2025. The flagship...

Company Drug

Tonghua Dongbao Secures Dominican Republic Market Launch for Insulin Aspart

Fineline Cube Nov 13, 2025

Tonghua Dongbao Pharmaceuticals Co., Ltd. (SHA: 600867) announced that its Insulin Aspart Injection 3 ml : 300 IU pre‑filled...

Company Drug

BCHT Receives NMPA Approval for First Adult DTaP Vaccine Covering Pertussis, Diphtheria, and Tetanus

Fineline Cube Nov 13, 2025

Changchun BCHT Biotechnology Co., Ltd. (SHA: 688276) announced that its Adsorbed Acellular Pertussis (Two‑Component) Diphtheria...

Company Deals Drug

EirGenix Secures $152 M Licensing Deal for EG1206A Breast‑Cancer Biosimilar from Sandoz

Fineline Cube Nov 13, 2025

EirGenix Inc. (TPE: 6589) announced a second, worldwide exclusive licensing agreement with Sandoz AG (SWX:...

Company Drug

Humanwell Initiates Phase 2 Trial of HW231019 Tablets for Post‑Abdominal Surgery Analgesia

Fineline Cube Nov 13, 2025

Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that it has begun a Phase 2 clinical...

Company Deals

Bio‑Sincerity Secures XPO1 Inhibitor Deal for BIOS‑0629, Aims at Solid‑Tumor Expansion

Fineline Cube Nov 13, 2025

Hangzhou Bio‑Sincerity Pharma‑Tech Co., Ltd. (SHE: 301096) announced that the company has signed a Technology...

Company

Bayer Reports Stable Q3 2025 Sales, Highlights Strong Nubeqa and Kerendia Growth

Fineline Cube Nov 13, 2025

Bayer AG (ETR: BAYN) announced on November 12 2025 that its third‑quarter 2025 (2025Q3) performance matched prior‑year...

Policy / Regulatory

FDA Announces New ‘Plausible‑Mechanism’ Pathway to Rapid Approvals for Rare Disease Treatments

Fineline Cube Nov 13, 2025

The U.S. Food and Drug Administration (FDA) announced on Wednesday a landmark regulatory shift that could...

Company Deals

Complete Genomics and SOPHiA Genetics Join Forces to Deliver End‑to‑End Oncology Validation on MGI’s T1+ Sequencing Platform

Fineline Cube Nov 13, 2025

Complete Genomics, the U.S. subsidiary of MGI Technologies (SHA: 688114), announced today a strategic collaboration...

Company Deals

Degron Therapeutics, MSD R&D, and the Next Generation of Molecular Glue Degraders

Fineline Cube Nov 13, 2025

Degron Therapeutics, a China‑based pioneer in protein‑degradation therapies, today announced the signing of a Letter...

Company Deals

Adicon Holdings, Crown Bioscience, and Global Lab Services Forge New Integrated Platform for Oncology Translational Research

Fineline Cube Nov 13, 2025

Adicon Holdings Ltd. (HKG: 9860), a leading independent clinic laboratory (ICL) service provider in China,...

Company Deals

AbbVie to End 11‑Year R&D Alliance with Alphabet‑Owned Calico Labs

Fineline Cube Nov 13, 2025

AbbVie Inc. (NYSE: ABBV) announced today that it will terminate its long‑standing collaboration agreement with...

Company Deals

ChengDa Biotechnology, IMCAS, and Beijing Key Laboratory for Synthetic Immunology Forge New Frontiers in Vaccine Manufacturing

Fineline Cube Nov 12, 2025

Liaoning ChengDa Biotechnology Co., Ltd. and the Institute of Microbiology, Chinese Academy of Sciences (IMCAS)...

Insight, China's Pharmaceutical Industry

C-Ray Therapeutics Partners with SHINE Technologies – Lu-177 Supply Agreement Targets China Radiopharmaceutical Market

GSK Partners with SPH Keyuan Trade to Relaunch Engerix B – Hepatitis B Vaccine Targets China’s Adult Self-Paid Market

MSD to Acquire Terns Pharmaceuticals for $6.7 Billion – TERN-701 BCR::ABL1 Inhibitor Targets Chronic Myeloid Leukemia

Daiichi Sankyo Partners with Tempus AI – Foundation Models Target ADC Biomarker Discovery and Patient Stratification

Thermo Fisher Partners with SHL Medical – Autoinjector Manufacturing Expansion Targets U.S. Drug-Device Combination Market

Novo Nordisk’s Awiqli Wins FDA Approval – World’s First Once-Weekly Basal Insulin for Type 2 Diabetes

Hengrui Pharma’s HRS9531 Wins NMPA Approval for Cardiovascular Outcomes Trial – Dual GIPR/GLP-1R Agonist Targets MACE Reduction

Qyuns Therapeutics Receives NMPA Trial Approvals for QX027N – Long‑Acting Bispecific Antibody Targeting Asthma and Atopic Dermatitis

Suzhou Zelgen Secures NMPA Trial Approval for ZG006 (Alveltamig) – First‑In‑Class Trispecific Antibody for Advanced Neuroendocrine Carcinoma

Adagene Licenses SAFEbody Platform to Third Arc Bio for Masked CD3 T‑Cell Engagers

Gan & Lee’s Ondibta Receives Positive CHMP Opinion – EU Biosimilar Pathway Opened

Corxel Secures FDA IND Clearance for CX11 Phase 2 Trial in Type 2 Diabetes

Pfizer Reduces BioNTech Holding by 54.7% While Collaboration Remains Intact

Jiangsu Hengrui’s Rezvilutamide Clears NMPA Hurdle, Moves Into Phase III Prostate‑Cancer Trial

Legend Biotech Reports $524 M CARVYKTI Sales, FDA Updates & Q3 Loss

Tonghua Dongbao Secures Dominican Republic Market Launch for Insulin Aspart

BCHT Receives NMPA Approval for First Adult DTaP Vaccine Covering Pertussis, Diphtheria, and Tetanus

EirGenix Secures $152 M Licensing Deal for EG1206A Breast‑Cancer Biosimilar from Sandoz

Humanwell Initiates Phase 2 Trial of HW231019 Tablets for Post‑Abdominal Surgery Analgesia

Bio‑Sincerity Secures XPO1 Inhibitor Deal for BIOS‑0629, Aims at Solid‑Tumor Expansion

Bayer Reports Stable Q3 2025 Sales, Highlights Strong Nubeqa and Kerendia Growth

FDA Announces New ‘Plausible‑Mechanism’ Pathway to Rapid Approvals for Rare Disease Treatments

Complete Genomics and SOPHiA Genetics Join Forces to Deliver End‑to‑End Oncology Validation on MGI’s T1+ Sequencing Platform

Degron Therapeutics, MSD R&D, and the Next Generation of Molecular Glue Degraders

Adicon Holdings, Crown Bioscience, and Global Lab Services Forge New Integrated Platform for Oncology Translational Research

AbbVie to End 11‑Year R&D Alliance with Alphabet‑Owned Calico Labs

ChengDa Biotechnology, IMCAS, and Beijing Key Laboratory for Synthetic Immunology Forge New Frontiers in Vaccine Manufacturing

You Missed

C-Ray Therapeutics Partners with SHINE Technologies – Lu-177 Supply Agreement Targets China Radiopharmaceutical Market

Novo Nordisk’s Awiqli Wins FDA Approval – World’s First Once-Weekly Basal Insulin for Type 2 Diabetes

Hengrui Pharma’s HRS9531 Wins NMPA Approval for Cardiovascular Outcomes Trial – Dual GIPR/GLP-1R Agonist Targets MACE Reduction

CStone Pharma 2025 Revenue RMB 269.6M Down 34% – NRDL Price Adjustment Hits Pralsetinib, Licensing Fees Decline